This concerned disease phenotypes, but there was also a clear trend towards higher disease activity in patients starting with anti-TNF agents ( Supplemental Table 1 ) suggesting that these aspects probably contributed to the choice of treatment.
← all excerpts
Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single-centre experience.
1
—
—